Moomoo AI 已提取核心訊息
On February 2, 2024, AbbVie Inc. reported its financial results for the fourth quarter and the full year that ended on December 31, 2023. The company experienced a decrease in full-year diluted EPS by 59.0% to $2.72 on a GAAP basis and a 19.3% decrease in adjusted diluted EPS to $11.11. Full-year net revenues declined by 6.4% to $54.318 billion, with a notable decrease in global net revenues from the immunology portfolio due to Humira biosimilar competition. However, the neuroscience portfolio saw an increase of 18.2% in global net revenues. The fourth-quarter diluted EPS also decreased by 66.7% to $0.46 on a GAAP basis and by 22.5% to $2.79 in adjusted diluted EPS. AbbVie also announced definitive agreements to acquire ImmunoGen and Cerevel Therapeutics, aiming to strengthen its oncology and neuroscience portfolios. The company provided an adjusted diluted EPS guidance range of $11.05 to $11.25 for 2024, which includes a dilutive impact from the aforementioned acquisitions. AbbVie reaffirmed its expectation for a high single-digit compound annual revenue growth rate through 2029 and raised its combined sales outlook for Skyrizi and Rinvoq to more than $27 billion by 2027.
On February 2, 2024, AbbVie Inc. reported its financial results for the fourth quarter and the full year that ended on December 31, 2023. The company experienced a decrease in full-year diluted EPS by 59.0% to $2.72 on a GAAP basis and a 19.3% decrease in adjusted diluted EPS to $11.11. Full-year net revenues declined by 6.4% to $54.318 billion, with a notable decrease in global net revenues from the immunology portfolio due to Humira biosimilar competition. However, the neuroscience portfolio saw an increase of 18.2% in global net revenues. The fourth-quarter diluted EPS also decreased by 66.7% to $0.46 on a GAAP basis and by 22.5% to $2.79 in adjusted diluted EPS. AbbVie also announced definitive agreements to acquire ImmunoGen and Cerevel Therapeutics, aiming to strengthen its oncology and neuroscience portfolios. The company provided an adjusted diluted EPS guidance range of $11.05 to $11.25 for 2024, which includes a dilutive impact from the aforementioned acquisitions. AbbVie reaffirmed its expectation for a high single-digit compound annual revenue growth rate through 2029 and raised its combined sales outlook for Skyrizi and Rinvoq to more than $27 billion by 2027.
2024年2月2日，艾伯維公司公佈了截至2023年12月31日的第四季度和全年財務業績。按公認會計原則計算，該公司的全年攤薄每股收益下降了59.0％，至2.72美元，調整後的攤薄每股收益下降了19.3％，至11.11美元。全年淨收入下降6.4％，至543.18億美元，由於Humira生物仿製藥的競爭，免疫學投資組合的全球淨收入顯著下降。但是，神經科學投資組合的全球淨收入增長了18.2％。按公認會計原則計算，第四季度攤薄後每股收益也下降了66.7％，至0.46美元，調整後的攤薄每股收益下降了22.5％，至2.79美元。艾伯維還宣佈了收購ImmunoGen和Cerevel Therapeutics...展開全部
2024年2月2日，艾伯維公司公佈了截至2023年12月31日的第四季度和全年財務業績。按公認會計原則計算，該公司的全年攤薄每股收益下降了59.0％，至2.72美元，調整後的攤薄每股收益下降了19.3％，至11.11美元。全年淨收入下降6.4％，至543.18億美元，由於Humira生物仿製藥的競爭，免疫學投資組合的全球淨收入顯著下降。但是，神經科學投資組合的全球淨收入增長了18.2％。按公認會計原則計算，第四季度攤薄後每股收益也下降了66.7％，至0.46美元，調整後的攤薄每股收益下降了22.5％，至2.79美元。艾伯維還宣佈了收購ImmunoGen和Cerevel Therapeutics的最終協議，旨在加強其腫瘤學和神經科學產品組合。該公司提供的2024年調整後的攤薄每股收益指導區間爲11.05美元至11.25美元，其中包括上述收購的攤薄影響。艾伯維重申了其對到2029年實現較高的個位數複合年收入增長率的預期，並將Skyrizi和Rinvoq的合併銷售前景提高到2027年超過270億美元。
有用
沒用